212 related articles for article (PubMed ID: 21694737)
1. Mortality in neurofibromatosis 1: in North West England: an assessment of actuarial survival in a region of the UK since 1989.
Evans DG; O'Hara C; Wilding A; Ingham SL; Howard E; Dawson J; Moran A; Scott-Kitching V; Holt F; Huson SM
Eur J Hum Genet; 2011 Nov; 19(11):1187-91. PubMed ID: 21694737
[TBL] [Abstract][Full Text] [Related]
2. Malignant peripheral nerve sheath tumours in neurofibromatosis 1.
Evans DG; Baser ME; McGaughran J; Sharif S; Howard E; Moran A
J Med Genet; 2002 May; 39(5):311-4. PubMed ID: 12011145
[TBL] [Abstract][Full Text] [Related]
3. Mortality associated with neurofibromatosis 1: a cohort study of 1895 patients in 1980-2006 in France.
Duong TA; Sbidian E; Valeyrie-Allanore L; Vialette C; Ferkal S; Hadj-Rabia S; Glorion C; Lyonnet S; Zerah M; Kemlin I; Rodriguez D; Bastuji-Garin S; Wolkenstein P
Orphanet J Rare Dis; 2011 May; 6():18. PubMed ID: 21542925
[TBL] [Abstract][Full Text] [Related]
4. Mortality in neurofibromatosis 1: an analysis using U.S. death certificates.
Rasmussen SA; Yang Q; Friedman JM
Am J Hum Genet; 2001 May; 68(5):1110-8. PubMed ID: 11283797
[TBL] [Abstract][Full Text] [Related]
5. Malignant peripheral nerve sheath tumours in NF1: improved survival in women and in recent years.
Ingham S; Huson SM; Moran A; Wylie J; Leahy M; Evans DG
Eur J Cancer; 2011 Dec; 47(18):2723-8. PubMed ID: 21700447
[TBL] [Abstract][Full Text] [Related]
6. Neurofibromatosis type 1 and sporadic optic gliomas.
Singhal S; Birch JM; Kerr B; Lashford L; Evans DG
Arch Dis Child; 2002 Jul; 87(1):65-70. PubMed ID: 12089128
[TBL] [Abstract][Full Text] [Related]
7. A clinical study of type 1 neurofibromatosis in north west England.
McGaughran JM; Harris DI; Donnai D; Teare D; MacLeod R; Westerbeek R; Kingston H; Super M; Harris R; Evans DG
J Med Genet; 1999 Mar; 36(3):197-203. PubMed ID: 10204844
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Cancer Prevalence in Patients With Neurofibromatosis Type 1 at an Academic Cancer Center vs in the General Population From 1985 to 2020.
Landry JP; Schertz KL; Chiang YJ; Bhalla AD; Yi M; Keung EZ; Scally CP; Feig BW; Hunt KK; Roland CL; Guadagnolo A; Bishop AJ; Lazar AJ; Slopis JM; McCutcheon IE; Torres KE
JAMA Netw Open; 2021 Mar; 4(3):e210945. PubMed ID: 33734413
[TBL] [Abstract][Full Text] [Related]
9. Management and prognosis of malignant peripheral nerve sheath tumors: The experience of the French Sarcoma Group (GSF-GETO).
Valentin T; Le Cesne A; Ray-Coquard I; Italiano A; Decanter G; Bompas E; Isambert N; Thariat J; Linassier C; Bertucci F; Bay JO; Bellesoeur A; Penel N; Le Guellec S; Filleron T; Chevreau C
Eur J Cancer; 2016 Mar; 56():77-84. PubMed ID: 26824706
[TBL] [Abstract][Full Text] [Related]
10. Mortality associated with neurofibromatosis type 1: a study based on Italian death certificates (1995-2006).
Masocco M; Kodra Y; Vichi M; Conti S; Kanieff M; Pace M; Frova L; Taruscio D
Orphanet J Rare Dis; 2011 Mar; 6():11. PubMed ID: 21439034
[TBL] [Abstract][Full Text] [Related]
11. Life expectancy, mortality and prognostic factors in neurofibromatosis type 1. A twelve-year follow-up of an epidemiological study in Göteborg, Sweden.
Zöller M; Rembeck B; Akesson HO; Angervall L
Acta Derm Venereol; 1995 Mar; 75(2):136-40. PubMed ID: 7604643
[TBL] [Abstract][Full Text] [Related]
12. Life expectancy in hereditary cancer predisposing diseases: an observational study.
Wilding A; Ingham SL; Lalloo F; Clancy T; Huson SM; Moran A; Evans DG
J Med Genet; 2012 Apr; 49(4):264-9. PubMed ID: 22362873
[TBL] [Abstract][Full Text] [Related]
13. Neurofibromatosis/Noonan phenotype: a variable feature of type 1 neurofibromatosis.
Colley A; Donnai D; Evans DG
Clin Genet; 1996 Feb; 49(2):59-64. PubMed ID: 8740913
[TBL] [Abstract][Full Text] [Related]
14. Neurofibromatosis type 1 growth charts.
Clementi M; Milani S; Mammi I; Boni S; Monciotti C; Tenconi R
Am J Med Genet; 1999 Dec; 87(4):317-23. PubMed ID: 10588837
[TBL] [Abstract][Full Text] [Related]
15. The Confidential Inquiry into premature deaths of people with intellectual disabilities in the UK: a population-based study.
Heslop P; Blair PS; Fleming P; Hoghton M; Marriott A; Russ L
Lancet; 2014 Mar; 383(9920):889-95. PubMed ID: 24332307
[TBL] [Abstract][Full Text] [Related]
16. [SENTIERI - Epidemiological Study of Residents in National Priority Contaminated Sites. Sixth Report].
Zona A; Fazzo L; Benedetti M; Bruno C; Vecchi S; Pasetto R; Minichilli F; De Santis M; Nannavecchia AM; Di Fonzo D; Contiero P; Ricci P; Bisceglia L; Manno V; Minelli G; Santoro M; Gorini F; Ancona C; Scondotto S; Soggiu ME; Scaini F; Beccaloni E; Marsili D; Villa MF; Maifredi G; Magoni M; Iavarone I;
Epidemiol Prev; 2023; 47(1-2 Suppl 1):1-286. PubMed ID: 36825373
[TBL] [Abstract][Full Text] [Related]
17. Regional variations in geographic access to inpatient hospices and Place of death: A Population-based study in England, UK.
Chukwusa E; Yu P; Verne J; Taylor R; Higginson IJ; Wei G
PLoS One; 2020; 15(4):e0231666. PubMed ID: 32302344
[TBL] [Abstract][Full Text] [Related]
18. Counting the lifetime cost of obesity: Analysis based on national England data.
Heald A; Stedman M; Fryer AA; Davies MB; Rutter MK; Gibson JM; Whyte M
Diabetes Obes Metab; 2024 Apr; 26(4):1464-1478. PubMed ID: 38312024
[TBL] [Abstract][Full Text] [Related]
19. Italian cancer figures, report 2012: Cancer in children and adolescents.
; ;
Epidemiol Prev; 2013; 37(1 Suppl 1):1-225. PubMed ID: 23585445
[TBL] [Abstract][Full Text] [Related]
20. Life expectancy and risk of death in 6791 communities in England from 2002 to 2019: high-resolution spatiotemporal analysis of civil registration data.
Rashid T; Bennett JE; Paciorek CJ; Doyle Y; Pearson-Stuttard J; Flaxman S; Fecht D; Toledano MB; Li G; Daby HI; Johnson E; Davies B; Ezzati M
Lancet Public Health; 2021 Nov; 6(11):e805-e816. PubMed ID: 34653419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
